An antibody for use in the depletion of cancer stem cells expressing EMP2 in a patient having a cancer and previously identified as comprising cancer stem cells that express EMP2 and one or more markers selected from the group consisting of CD44, CD 133 ABCG2, and ALDH, wherein: a) the antibody comprises a heavy chain having the amino acid sequence: MAQVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRRGRKSAGIDYWGQGTLVTVSS, and a light chain having the amino acid sequence: b) the antibody comprises a heavy chain having the amino acid sequence: MAQVQLVQSGGGLVQPGRSLRLSCAASGFSFSEYPMHWVRQAPGRGLESVAVISYDGEYQKYADSVKGRFTISRDDSKSTVYLQMNSLRPEDTAVYYCARTINNGMDVWGQGTTVT, and a light chain having the amino acid sequence: c) the antibody comprises a heavy chain having the amino acid sequence: MAQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTVGATGAFDIWGQGTMVTVSSS, and a light chain having the amino acid sequence: d) the antibody comprises a heavy chain having the amino acid sequence: MAQVQLVQSGGGLVQPGRSLRLSCAASGFSFSEYPMHWVRQAPGRGLESVAVISYDGEYQKYADSVKGRFTISRDDSKSTVYLQMNSLRPEDTAVYYCARTINNGMDVWGQGTTVT, and a light chain having the amino acid sequence: e) the antibody competes for binding to EMP2 with an antibody according to a), b), c), or d); f) the antibody shares 90% amino acid identity with heavy and light chain variable regions of an antibody according to a), b), c), or d); or g) the antibody comprises CDR sequences identical to those of an antibody according to a), b), c), or d). a) the antibody comprises a heavy chain having the amino acid sequence: MAQVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRRGRKSAGIDYWGQGTLVTVSS, and a light chain having the amino acid sequence: MAQVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRRGRKSAGIDYWGQGTLVTVSS, and a light chain having the amino acid sequence: b) the antibody comprises a heavy chain having the amino acid sequence: MAQVQLVQSGGGLVQPGRSLRLSCAASGFSFSEYPMHWVRQAPGRGLESVAVISYDGEYQKYADSVKGRFTISRDDSKSTVYLQMNSLRPEDTAVYYCARTINNGMDVWGQGTTVT, and a light chain having the amino acid sequence: MAQVQLVQSGGGLVQPGRSLRLSCAASGFSFSEYPMHWVRQAPGRGLESVAVISYDGEYQKYADSVKGRFTISRDDSKSTVYLQMNSLRPEDTAVYYCARTINNGMDVWGQGTTVT, and a light chain having the amino acid sequence: c) the antibody comprises a heavy chain having the amino acid sequence: MAQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTVGATGAFDIWGQGTMVTVSSS, and a light chain having the amino acid sequence: MAQVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARTVGATGAFDIWGQGTMVTVSSS, and a light chain having the amino acid sequence: d) the antibody comprises a heavy chain having the amino acid sequence: MAQVQLVQSGGGLVQPGRSLRLSCAASGFSFSEYPMHWVRQAPGRGLESVAVISYDGEYQKYADSVKGRFTISRDDSKSTVYLQMNSLRPEDTAVYYCARTINNGMDVWGQGTTVT, and a light chain having the amino acid sequence: MAQVQLVQSGGGLVQPGRSLRLSCAASGFSFSEYPMHWVRQAPGRGLESVAVISYDGEYQKYADSVKGRFTISRDDSKSTVYLQMNSLRPEDTAVYYCARTINNGMDVWGQGTTVT, and a light chain having the amino acid sequence: e) the antibody competes for binding to EMP2 with an antibody according to a), b), c), or d); f) the antibody shares 90% amino acid identity with heavy and light chain variable regions of an antibody according to a), b), c), or d); or g) the antibody comprises CDR sequences identical to those of an antibody according to a), b), c), or d).